Anti-HDAC6 antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

HDAC6 or histone deacetylase 6 is a protein that primarily functions as a cytoplasmic deacetylase. It is part of the class IIb HDAC family and is known for its distinctive molecular weight of approximately 121 kDa. HDAC6 is expressed in various tissues with higher levels observed in the brain kidney and liver. This protein is unique as it contains two catalytic domains unlike other HDACs which contributes to its specific deacetylation of non-histone substrates including tubulin and Hsp90 influencing cell motility and stress response.

Biological function summary

HDAC6 plays a significant role in processes like protein degradation and cell signaling. It is an important component of the protein quality control system involving itself in the aggresome pathway where it facilitates the removal of misfolded proteins through interaction with dynein motor proteins. In addition to its presence in the cytoplasm HDAC6 influences cell migration and immune response regulation by de-phosphorylating cortactin and affecting actin filament dynamics. Its integral role in the aggresome-autophagy pathway positions it as important for cellular homeostasis maintenance.

Pathways

HDAC6 participates prominently in both autophagy and stress response pathways. In the autophagic process HDAC6 operates alongside ubiquitinated proteins to manage protein quality control. Moreover HDAC6 engages in stress response pathways like the heat shock response interacting directly with Hsp90 to regulate client protein activation. These pathways highlight HDAC6’s relationships with key proteins such as Hsp70 and tau linking it to cellular stress and neurodegeneration responses.

Associated diseases and disorders

HDAC6 exhibits connections to neurodegenerative diseases and cancer. Dysregulated HDAC6 activity associates with Alzheimer's disease where it affects tau protein accumulation and degradation. The protein is also implicated in various cancers such as breast and ovarian cancer due to its influence on cell migration and invasion. It interacts with p53 impacting apoptosis and tumor progression making HDAC6 a potential target for therapeutic interventions with HDAC6 inhibitors which aim to restore normal cellular functions disrupted by abnormal HDAC6 activity.